Until recently, interest in the role of platelets in inflammatory bowel disease (IBD) was confined to an awareness of thrombocytosis as a marker of disease activity,' and as a possible predisposing factor to systemic thromboembolism. Two recent conceptual advances suggest that platelets may contribute to the pathogenesis of IBD at the mucosal level. Firstly, it is now recognised that platelets themselves participate in the inflammatory response by acting as a potent source of inflammatory mediators and modulating the activity of other inflammatory cells.2 Secondly, multifocal microinfarction in the mesenteric vasculature has been proposed as an early event in the pathogenesis of Crohn's disease3; this hypothesis has drawn attention again to earlier speculation about a vascular origin for ulcerative colitis.4 5 We discuss here the evidence for a pathogenic role for platelets in IBD, and possible therapeutic implications of this.
Platelets as inflammatory celis Platelets are capable of directly eliciting an inflammatory response. Injection of extracts of platelets into the skin of healthy volunteers produces a strong inflammatory reaction -rubor, dolor, calor, and turgor -which persists for several hours.6 Extracts of neutrophils and basophils fail to produce this reaction and eosinophils give only an early histamine-like response. Over the last two decades, the proinflammatory properties of platelets have gradually been elucidated2; those which may be important in IBD are described.
RELEASE OF INFLAMMATORY MEDIATORS
Activated platelets release a range of inflammatory mediators including platelet activating factor (PAF), thromboxane (TX), 1 2-hydroxyeicosatetraenoic acid (12-HETE), platelet factor 4 (PF4), serotonin, platelet derived growth factor (PDGF), and transforming growth factor beta (TGF(). Platelets are also capable of producing oxygen free radicals, via IgE receptor mediated activation.7 As well as contributing to promote mitogenesis in fibroblasts20 14 and may thereby stimulate local fibrosis and angiogenesis.
Platelets in vascular disease
In view of the compelling evidence that abnormalities within mesenteric blood vessels contribute to the pathogenesis of IBD,3-5 it is of interest that abnormal platelet behaviour is seen in other disorders in which vascular pathology is a feature.
In ischaemic heart disease, for example, increased platelet aggregation in vitro21 22 and increased mean platelet volume23 predict coronary events and mortality. Moreover, antiplatelet therapy is of proved benefit in reducing morbidity and mortality. 24 and increased sensitivity to adenosine diphosphate, arachidonic acid, ristocetin, collagen, and thrombin32-34 has also been described. PLATELET The functional status of circulating platelets in vivo can be assessed using single cell flow cytometry. The glycoproteins P-selectin (the neutrophil adhesion molecule) and GP53 (whose function is unknown) are extruded to the platelet surface membrane during activation and can be detected using specific fluorescent antibodies. Increased expression of these markers is seen in peripheral venous blood in Crohn's disease and in ulcerative colitis, independently of disease activity.36 37 Why are platelet function and morphology abnormal in IBD? There are several possible mechanisms for increased platelet activation in IBD. Endothelial cell damage in the mesenteric vasculature exposes basement membrane collagen, to which platelets are exquisitely sensitive, and this could trigger platelet activation. The increase in serum von Willebrand factor (a marker of endothelial cell damage) found in IBD, in Crohn's disease independently of disease activity, is consistent with this possibility. 46 Release of PAF47 and thromboxane A233 from platelets or activated neutrophils into the mesenteric circulation at the site of intestinal disease could perpetuate or amplify platelet activation; monocytes and neutrophils activated by endotoxin48 or other absorbed bacterial products could also stimulate platelets.49 Virus induced changes in the endothelium could promote platelet adherence and activation in vitro before any detectable endothelial cell disruption50; this observation is particularly interesting in the light of the recent report of persisting measles infection in foci of granulomatous vasculitis in Crohn's disease tissue. 5 1 The evidence relating to platelet count, size, and survival is as yet more difficult to explain. Circulating platelet count is the net result of the balance between rates of production and destruction. Factors responsible for stimulating thrombopoiesis include interleukins 3 and 6, and thrombopoietin,52 and circulating interleukin 6 at least is raised in active Crohn's disease.53 The published data suggesting that, despite being activated, platelets in IBD are small33 43 44 presents a paradox: in ischaemic heart and diabetic vascular disease, for example, platelets are activated but large,23 27 consistent with previous evidence that the reactivity of subpopulations of platelets correlates positively with their volume.54 Platelet size is probably determined at the time of thrombopoiesis; no significant change takes place during the time the individual platelet spends in the circulation.55 Determination of platelet size is complex and is influenced by megakaryocyte volume and ploidy.56 Platelet destruction rate, platelet thromboxane production, and the bleeding time contribute to the complex feedback mechanism which determines the properties of megakaryocytes56; different profiles of these variables in IBD and ischaemic heart disease may account for the contrasting mean platelet volume in these diseases. Alternatively, reduced mean platelet volume in the peripheral circulation in IBD could be explained by consumption or sequestration of large activated platelets in the intestinal vasculature. Although such a phenomenon would contribute to reduced platelet survival, attempts to image sequestration in the mesenteric vasculature in IBD using radiolabelled platelets have proved inconclusive so far. 33 Pathogenetic consequences of abnormal platelet function in IBD Activated hyperaggregable platelets may contribute to the pathogenesis of the mucosal lesion in IBD by local release of inflammatory mediators, and chemoattraction and activation of other inflammatory cells, as described earlier.
Platelet phospholipid membrane is the primary site for assembly of the coagulation factors essential for the generation of thrombin and consequently fibrin57; it is therefore possible that a platelet abnormality underlies the procoagulant state observed in IBD. Expression of P-selectin on the platelet surface membrane promotes neutrophil accumulation and fibrin deposition at the site of vascular injury. 
